Background
A global pharmaceutical company had several therapies in the Virology space that were capable of curing or preventing the spread of serious illnesses. This team had made great strides in identifying and activating patients to cure or stop the spread of disease, with over 90% of estimated populations of patients with these diseases already identified and on treatment. To truly eliminate these diseases, the team was determined to find and activate the small remaining population, but didn’t know how to reach them as so many avenues had already been explored.